A novel immunotherapy for non-muscle invasive bladder cancer (NMIBC).
HOPEC Pharma is developing Inactivated UPEC-FimON, a first-in-class immunotherapy designed to transform the treatment of NMIBC. Our mission is to bring safe, effective, and accessible innovation to patients worldwide.
TRANSFORMING BLADDER CANCER TREATMENT
COLLABORATIONS AND PARTNERSHIPS
Strategic partnerships drive Hopec Pharma’s mission to transform bladder cancer treatment. By collaborating with leading research institutions, healthcare providers, and industry leaders, we accelerate innovation and deliver life-changing therapies to patients worldwide.
KEY ACHIEVEMENTS
Strategic Partnerships
Secured exclusive licensing for UPEC-FimON with top Israeli institutions.
Manufacturing Strength
Partnered with 'Scinai Immunotherapeutics'
for scalable GMP-certified, production.
Clinical Trial Readiness
Phase 1a/1b multicenter clinical trials initiated in Q4 2025 at Hadassah and Sheba Medical Centers.
R&D Advancements
Breakthrough research in immune mechanisms via single-cell RNA-seq studies.